Considering the infrequent occurrence of BRAF mutations in glioblastoma, there is little clinical data on the efficacy of BRAF inhibitors in glioblastoma specifically, rather, clinical trials may include all types of BRAF V600E-mutant glioma. The gene discussed is BRAF; the disease is glioma.